I
Innomedica
Pharmaceuticals efficiently targeted
About Innomedica
Innomedica operates as a Swiss biopharmaceutical company, concentrating on the advancement of drug delivery systems through nanotechnology. The firm was initially established as a finance company in 2000. A pivotal shift occurred in January 2013 when it transitioned into an operationally independent pharmaceutical entity, a move catalyzed by the acquisition of the Japanese company YAMAZAKI-DDS Co., Ltd. This acquisition provided Innomedica with access to a nanotechnology platform that had undergone over two decades of research and patenting.
The company's core business revolves around a proprietary, patent-protected nanocarrier technology platform. This technology utilizes liposomes, which are artificially created vesicles, to encapsulate active pharmaceutical ingredients. The objective is to enable the targeted delivery of drugs to specific sites within the body, thereby improving therapeutic efficacy while simultaneously reducing side effects. The platform is designed to be versatile, capable of being used with both established clinical drugs and novel substances like RNA or proteins. Innomedica's business model includes forming international research collaborations and establishing licensing agreements to enter global markets. The company also operates its own GMP-certified 'Nanofactory' in Marly, Switzerland, ensuring control over the entire value chain from production to the final sterile product.
Innomedica's product pipeline is focused on significant therapeutic areas, primarily oncology and neurodegenerative diseases. A key development in its oncology portfolio is Talidox®, a liposomal formulation of the established chemotherapy agent doxorubicin. This product is engineered to deliver the drug directly to tumor tissue in high concentrations, potentially reducing severe side effects like heart problems, hair loss, and nausea associated with conventional chemotherapy. Clinical trials for Talidox began in November 2018 for treating advanced metastatic solid tumors, breast cancer, and ovarian cancer. In the neurology space, the company is developing a treatment for neurodegenerative conditions such as Parkinson's disease. This product utilizes a nanocarrier designed to cross the blood-brain barrier to deliver neuroprotective agents. The first Parkinson's patient was treated in a clinical study in December 2021.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VC✓Equity / VC | Dec 2021 | $16M | $65M | Undisclosed | ↗ |
| LATE VC✓Equity / VC | Jul 2018 | $10M | $41M | Undisclosed | — |
Growth signals
Latest recorded traffic for Innomedica is 920 monthly website visits, up 24.3% over the last three months. Innomedica's team declined 5.4% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Innomedica in the Bern ecosystem
The Innomedica office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Innomedica on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Innomedica’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









